Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

Stopped early

Conditions studied: Hepatitis C

In brief

This is a long-term safety follow-up protocol for subjects who received TT-034 under the B2801001 protocol and consists of monitoring for at least 4.5 years.

Key facts

Study ID

NCT02315638

Run by

Tacere Therapeutics, Inc.

People needed

9

Starts

2014-11-01

Expected to finish

2018-09-24

Last updated by the study team

2018-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prior enrollment in Study B2801001 and dosing with TT-034
• An informed consent form for this study signed and dated by the subject or a legally acceptable representative

You may not qualify if…

• There are no specific exclusion criteria for this follow-up study

Where it is running

• Duke Clinical Research Institute — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.